SGI
ENTA icon

Summit Global Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Summit Global Investments’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,600
Closed -$564K – 268
2018
Q3 		$564K Buy
6,600
+500
+8% +$50.1K 0.08% 237
2018
Q2 		$707K Buy
+6,100
New +$609K 0.11% 141

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Summit Global Investments's ENTA Position: Q4 2018 in Review

Summit Global Investments sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 6,600 shares — an estimated $564K sold.

Summit Global Investments first reported a position in ENTA in Q2 2018 and held it in 2 quarters. The position peaked at $707K in Q2 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Summit Global Investments reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Summit Global Investments sold 6,600 Enanta Pharmaceuticals shares in Q4 2018, an estimated $564K.
  • Summit Global Investments first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Summit Global Investments's Enanta Pharmaceuticals position peaked at $707K in Q2 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Summit Global Investments's 13F filing for Q4 2018, filed 8 Feb 2019.